Department of 2nd Urology, Atatürk Teaching and Research Hospital, Aydınlıkevler Mahallesi Arılık Sokak No: 5/5, P.O. Box 06130, Ankara, Turkey.
Int Urol Nephrol. 2011 Mar;43(1):79-83. doi: 10.1007/s11255-010-9774-z. Epub 2010 Jun 10.
To compare the efficiency and spontaneous expulsion rates of tamsulosin and Rowatinex in patients with distal ureteral stones.
Between March and July 2009, 90 patients with distal ureteral stones <10 mm in size were included in the study. Patients were randomized in 3 groups: Group 1 (n = 31, those received 0.4 mg tamsulosin once daily), Group 2 (n = 30, those received 100 mg Rowatinex capsules 3 times a day), and Group 3 (n = 29, those received diclofenac 100 mg once daily). All patients were followed up for 10 days.
Mean age of the patients was 42.4 ± 16.1 (range, 22-75), 46.5 ± 16.5 (range, 22-76), and 43.5 ± 16.6 (range, 18-71) years in Groups 1-3, respectively. On admission, 37.8% had hematuria and 78.9% had lower urinary tract symptoms (LUTS). No statistically significant differences were detected between the three groups regarding patient age, gender, mean stone size, stone location, stone site, additional analgesic requirement, number of ureteral colics during the treatment, and upper urinary tract dilation. The mean stone expulsion time was 3.5 days in Group 1, 6 days in Group 2, and 7 days in Group 3 (P = 0.02). Stone expulsion rate was significantly high in Group 1 compared to Group 2 (P = 0.002). Similarly, stone expulsion rate was significantly high in Group 1 compared to Group 3 (P = 0.001). Medical treatment with tamsulosin seems to be effective in patients with distal ureteral stones <10 mm in size. However, use of Rowatinex does not seem to have any significant effect on clearance rate of distal ureteral calculi.
比较坦索罗辛和罗通宁在治疗输尿管下段结石患者中的疗效和自发排出率。
2009 年 3 月至 7 月，共纳入 90 例大小＜10mm 的输尿管下段结石患者。将患者随机分为 3 组：组 1（n=31，每日口服坦索罗辛 0.4mg）、组 2（n=30，每日口服罗通宁胶囊 3 次，每次 100mg）和组 3（n=29，每日口服双氯芬酸 100mg）。所有患者均随访 10 天。
患者平均年龄分别为组 1（n=31）42.4±16.1 岁（年龄范围 22-75 岁）、组 2（n=30）46.5±16.5 岁（年龄范围 22-76 岁）和组 3（n=29）43.5±16.6 岁（年龄范围 18-71 岁）。入院时，37.8%的患者有血尿，78.9%的患者有下尿路症状（LUTS）。三组患者在年龄、性别、结石平均大小、结石位置、结石部位、额外镇痛需求、治疗期间输尿管绞痛次数、上尿路扩张等方面均无统计学差异。组 1 的平均结石排出时间为 3.5 天，组 2 为 6 天，组 3 为 7 天（P=0.02）。组 1 的结石排出率明显高于组 2（P=0.002）。同样，组 1 的结石排出率明显高于组 3（P=0.001）。坦索罗辛治疗对大小＜10mm 的输尿管下段结石患者有效。然而，罗通宁对输尿管下段结石清除率似乎没有明显影响。
